Altered microRNAs in STHdhQ111/HdhQ111 cells: miR-146a targets TBP

Biochemical and Biophysical Research Communications

Volumn 396, Issue 3, 2010, Pages 742-747

  Sinha, Mithun ^a   Ghose, Jayeeta ^a   Das, Eashita ^a   Bhattarcharyya, Nitai P ^a  

^a SAHA INSTITUTE OF NUCLEAR PHYSICS   (India)

Author keywords

MicroRNA 146a; STHdhQ111 HdhQ111 cells; Tata Binding Protein

Indexed keywords

MICRORNA; MICRORNA 146A; TATA BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; UPREGULATION;

ANIMALS; CELL LINE; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; HUNTINGTON DISEASE; LUCIFERASES; MICE; MICE, KNOCKOUT; MICRORNAS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; TATA-BOX BINDING PROTEIN;

EID: 77953025795     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.007     Document Type: Article

References (39)

1. Liu J. Control of protein synthesis and mRNA degradation by microRNAs. Curr. Opin. Cell Biol. 20 (2008) 214-221
2. Lewis B.P., Burge C.B., and Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120 (2005) 15-20
3. Vo N., Klein M.E., Varlamova O., et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl. Acad. Sci. USA 102 (2005) 16426-16431
4. Hermeking H. p53 enters the microRNA world. Cancer Cell 12 (2007) 414-418
5. Ruepp A., Kowarsch A., Schmidl D., et al. PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes. Genome Biol. 11 (2010) R6 (Epub ahead of print)
6. Jiang Q., Wang Y., Hao Y., et al. MiR2Disease: a manually curated database for microRNA deregulation in human disease. Nucl. Acid Res. 37 (2009) D98-D104
7. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
8. Imarisio S., Carmichael J.V., Korolchuk V., et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 412 (2008) 191-209
9. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 83 (2007) 228-248
10. Sugars K.L., and Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19 (2003) 233-238
11. Zucatto C., Tartari M., Crotti A., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE controlled neuronal genes. Nat. Genet. 35 (2003) 76-83
12. Benn C.L., Sun T., Sadri-Vakili G., et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci. 28 (2008) 10720-10733
13. Johnson R., Zuccato C., Belyaev N.D., et al. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis. 29 (2008) 438-445
14. Packer A.N., Xing Y., Harper S.Q., et al. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28 (2008) 14341-14346
15. P. Lau, B. de Strooper, Dysregulated microRNAs in neurodegenerative disorders, Semin. Cell Dev. Biol. 2010 (Epub ahead of print).
16. Burton A. Possible role for p53 in Huntington's disease. Lancet Neurol. 4 9 (2005) 528-529
17. Savas J.N., Makusky A., Ottosen S., et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc. Natl. Acad. Sci. USA 105 (2008) 10820-10825
18. Suzuki H.I., Yamagata K., Sugimoto K., et al. Modulation of microRNA processing by p53. Nature 460 (2009) 529-533
19. Trettel F., Rigamonti D., Hilditch-Maguire P., et al. Dominant phenotypes produced by the HD mutation in STHdh (Q111) striatal cells. Hum. Mol. Genet. 9 (2000) 2799-2809
20. Peltier H.J., and Latham G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14 (2008) 844-852
21. Xiao F., Zuo Z., Cai G., et al. MiRecords: an integrated resource for microRNA-target interactions. Nucl. Acids Res. 37 (2009) D105-D110
22. Taganov K.D., Boldin M.P., Chang K.J., et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103 (2006) 12481-12486
23. Chen C., Ridzon D.A., Broomer A.J., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucl. Acids Res. 33 (2005) e179
24. Gines S., Ivanova E., Seong I.S., et al. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-d-aspartate receptor activation in Huntington's disease knock-in striatal cells. J. Biol. Chem. 278 (2003) 50514-50522
25. Gines S., Seong I.S., Fossale E., et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 12 (2003) 497-508
26. Lee J.M., Ivanova E.V., Seong I.S., et al. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet. 3 8 (2007) e135
27. Quintanilla R.A., Jin Y.N., Fuenzalida K., et al. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem. 283 (2008) 25628-25637
28. Xifró X., García-Martínez J.M., Del Toro D., et al. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J. Neurochem. 105 (2008) 596-612
29. Kong P.J., Kil M.O., Lee H., et al. Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. Neurol. Res. 31 (2009) 77-83
30. Subramaniam S., Sixt K.M., Barrow R., et al. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324 (2009) 1327-1330
31. Wu J., and Xie X. Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol. 7 (2006) R85
32. Tarasov V., Jung P., Verdoodt B., et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6 (2007) 1586-1593
33. Bae B.I., Xu H., Igarashi S., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 (2005) 29-41
34. Huang C.C., Faber P.W., Persichetti F., et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24 (1998) 217-233
35. Schaffar G., Breuer P., Boteva R., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 15 (2004) 95-105
36. Kazemi-Esfarjani P., and Benzer S. Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum. Mol. Genet. 11 (2002) 2657-2672
37. Fujigasaki H., De Martin J., Deyn P.P., et al. CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. Brain 124 (2001) 1939-1947
38. Friedman M.J., Shah A.G., Fang Z.H., et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat. Neurosci. 10 (2007) 1519-1528
39. Friedman M.J., Wang C.E., Li X.J., and Li S. Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J. Biol. Chem. 283 (2008) 8283-8290